ADC Development for Gliomas

Improvements in antibody-drug conjugate (ADC) technology, such as the advent of tumor specific antibodies, universal testing of chimeric or humanized antibodies, improved linker technology and more potent cytotoxic payloads, have increased the appeal in using ADC agents in the treatment of patients with gliomas. Highlighted by platforms of monoclonal antibody (mAb) engineering and drug discovery, Creative Biolabs has provided customized ADC development services for clients all over the world. Scientists from Creative Biolabs are capable of designing and performing different ADC constructs against gliomas. We have been dedicating ourselves to helping every customer to facilitate their projects in a highly productive and cost-effective way.

Introduction of Gliomas

Gliomas are the most common type of primary brain tumor. Nearly two-thirds of gliomas are highly malignant lesions that account for a disproportionate share of brain tumor-related morbidity and mortality. The most widely used current classification of human gliomas is that of the World Health Organization (WHO), revised in 2000, which divides diffuse gliomas into astrocytic tumors, oligodendrogliomas, and oligoastrocytomas. These are then graded into histological degrees of malignancy shown in Figure 1.

Gliomas classification. Fig.1 Gliomas classification. (Taal, 2015)

A glioma can affect brain function and be life-threatening depending on its location and rate of growth. Thus, it also differentiates into low grade or benign glioma and a high grade or malignant glioma. The symptoms of glioma vary by tumor type as well as the tumor's size, location and rate of growth. Common signs and symptoms of gliomas include nausea or vomiting, headache, confusion or a decline in brain function, memory loss, difficulty with balance, vision problems and so on. The exact cause of gliomas is not known but there are some risk factors, such as age, exposure to radiation, family history of glioma.

Diagnosis and Treatment of Glioma

Glioma though is a slowly progressing tumor, its prognosis is not very good. There is no cure and the only aim of treatment is to bring down its growth and to manage symptoms. The survival rate from the time of diagnosis is on an average 12 months but with better modalities of treatment coming up a median survival of up to 11 to 12 years. Again, the life expectancy depends on whether the tumor is benign or malignant with the latter carrying lesser years of survival. Surgery, radiation, and chemotherapy have been the mainstays of therapy for most glioma patients, temozolomide chemotherapy has recently been proven to prolong overall survival in patients with glioblastoma. Novel treatment approaches, especially targeted molecular therapies against critical components of glioma signaling pathways, appear promising in preliminary studies.

ADC Development for Gliomas

ADC Therapy for Gliomas

Besides immunotoxins and radioimmunotherapy, one major group of immunotherapies that has been extensively trialed for the treatment of patients with gliomas is ADC. Exploiting molecular targets/biomarkers such as EGFR and then developing corresponding target-specific ADCs is a promising strategy to develop therapeutics with the potential to improve survival in patients with Glioma. For instance, studies revealed that an anti–EGFRvIII-specific fully human ADC, AMG 595, demonstrated potent efficacy in vitro and in preclinical subcutaneous models/orthotopic model of Glioma. Currently, AMG 595 is being tested in clinical trials with early signs of efficacy.

What Can We Do for You?

Creative Biolabs' improved understanding of the molecular characteristics of gliomas has led to the recognition of potential antigen targets for ADC therapies for challenging glioma tumors. You can maximize your investment and streamline your ADC development program by utilizing our expertise and state-of-the-art facilities at every stage of the process. From assessing the efficacy of different conjugation and linker technologies to the synthesis of cytotoxic payloads, we can support and guide you in the development of a matrix of candidates that can be tested to find the ideal ADC for your projects. Armed with advanced technique platforms, Creative Biolabs provides personalized anti-glioma ADC related services including but not limited to the target-specific antibody preparation and modification, customized linker-payload complex synthesis, antibody conjugation, ADC products analysis and characterization. Creative Biolabs is focusing on applying excellent science and technology to discover and develop potential new ADCs. We now provide one-stop ADC Development services for Glioblastoma to promote your ADC discovery program.

ADC Development for Gliomas

The human mAb-drug conjugates constitute a potential new approach for the treatment of malignant gliomas. Equipped with perfect mAb development platforms and well-developed linker-payload synthesis and ADC conjugation platform, Creative Biolabs provides a comprehensive set of ADC development services for customer all over the world. If you are interested in our ADC development services, please don't hesitate to contact us for more information.

Reference

  1. Taal, W.;et al. Chemotherapy in glioma. CNS oncology. 2015, 4(3): 179-192.


Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top